

Ref. No: 460  
From: Commercial  
Date: 13/03/23  
Subject: Biologic and targeted medications (Dermatology / Respiratory Medicine)

## REQUEST

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

1. How many patients were treated in February 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

2. How many patients were treated in February 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Mepolizumab (Nucala)
- Tezepelumab (Tezspire)

## RESPONSE

Data captured between 1<sup>st</sup> February 2023 to 1<sup>st</sup> March 2023.

1.

Drug	Patient Numbers
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	<5
Dupilumab (Dupixent)	23
Omalizumab (Xolair)	8
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	<5

2.

<b>Drug</b>	<b>Patient Numbers</b>
Benralizumab (Fasenra)	0
Dupilumab (Dupixent)	0
Omalizumab (Xolair)	0
Reslizumab (Cinqaero)	0
Mepolizumab (Nucala)	0
Tezepelumab (Tezspire)	0

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.